Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Sweep Away Senile Cells

PAIN'S SECRET MESSAGE: Why Prince Didn't Need to Die

7 Natural Ways to Prevent Diabetes

8 Hacks to Slash Medication Costs

New Study Shows Optimized Curcumin Stops Inflammation

Relief from Common Digestive Distress

What Foods Can Help Fight the Risk of Chronic Inflammation?

Block The Vascular Origins Of Cognitive Decline

SURVEY: Should Opioids Be Restricted for Chronic Illness?

Curcumin: Your Secret Weapon to Speed Muscle Recovery After Intense Exercise

 
Print Page
Email Article

Profile of adverse events with duloxetine [Cymbalta] treatment: a pooled analysis of placebo-controlled studies – Source: Drug Safety, May 1, 2010

  [ 58 votes ]   [ Discuss This Article ]
By S Brunton, et al. • www.ProHealth.com • April 22, 2010


The serotonin and noradrenaline (norepinephrine) reuptake inhibitor duloxetine [brand names Cymbalta, Yentreve] has been approved in the US and elsewhere for a number of indications, including psychiatric illnesses and chronic pain conditions.

Because the patient populations are diverse within these approved indications, and duloxetine is not yet approved for treatment of other conditions, we wanted to determine if adverse event profiles would differ among patients being treated for these various conditions.

To provide detailed information on the adverse events associated with duloxetine and to identify differences in the adverse event profile between treatment indications and patient demographic subgroups.

Data were analyzed from all placebo-controlled trials of duloxetine completed as of December 2008. The 52 studies included 17,822 patients (duloxetine n = 10 326; placebo n = 7496) with major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, osteoarthritis knee pain (OAKP), chronic lower back pain and lower urinary tract disorders.

The main outcome measures were rates of treatment-emergent adverse events (TEAEs) and adverse events reported as the reason for discontinuation.

• The overall TEAE rate was 57.2% for placebo-treated patients and 72.4% for duloxetine-treated patients (p = 0.001 or less).

• Patients with osteoarthritis knee pain had the lowest TEAE rate (placebo 36.7% vs duloxetine 50.2% (p = 0.01 or less),

• While patients with fibromyalgia had the highest rate (placebo 80.0% vs duloxetine 89.0% (p = 0.001 or less).

The most common TEAE for all indications was nausea (placebo 7.2% vs duloxetine 23.4% (p = 0.001 or less), which was predominantly mild to moderate in severity. No statistically significant treatment-by-subgroup interactions for age were found between placebo and duloxetine treatment for the most common TEAEs.

The rates of duloxetine-associated dry mouth and fatigue were greater in women than in men (13.1% vs 10.4%, interaction p = 0.004; and 9.4% vs 7.6%, interaction p = 0.03, respectively).

Duloxetine-associated dry mouth incidence was higher in Caucasians than non-Caucasians (13.2%, 11.0%, interaction p = 0.04).

Duloxetine treatment is associated with significantly higher rates of common TEAEs versus placebo, regardless of indication or demographic subgroup.

Differences across indications are likely to be attributable to the underlying condition rather than duloxetine, as suggested by the similar trends observed in placebo- and duloxetine-treated patients.

Source: Drug Safety, May 2010;33(5):393-407. PMID: 20397739, by Brunton S, Wang F, Edwards SB, Crucitti AS, Ossanna MJ, Walker DJ, Robinson MJ. Faculty Development, Cabarrus Family Medicine Residency, Concord, North Carolina, USA.





Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra EPA  - Fish Oil Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
20 Helpful Tips for Cleaning and Organizing When You're Chronically Ill

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health
Aching Muscles? Top 10 Nutrients to Take Back Your Life Aching Muscles? Top 10 Nutrients to Take Back Your Life
Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler

· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map